What is MaxCyte's stock-based comp?

MaxCyte (MXCT) reported stock-based comp of $1.14M in Q1 2026.

How has MaxCyte's stock-based comp changed year-over-year?

MaxCyte's stock-based comp decreased by 62.5% year-over-year, from $3.04M to $1.14M.

What is the long-term trend for MaxCyte's stock-based comp?

Over 4 years (2021 to 2025), MaxCyte's stock-based comp has grown at a 3.7% compound annual growth rate (CAGR), from $7.96M to $9.21M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

MaxCyte MXCT Stock-Based Comp

Stock-Based Comp at other companies

Thermo Fisher ScientificTMO

$83M+10.7%

Ginkgo BioworksDNA

$15.85M-8.8%

Immix Biopharma, Inc.IMMX

$575.57K-33.7%

Rapid Micro BiosystemsRPID

$1.22M+17.4%

PDE

Pro-Dex, Inc.PDEX

$186K+17.7%

RepligenRGEN

$8.32M+14.4%

Segments

By segment

See full

Cell Engineering Technology$1.14M-62.5%

Other financials

Income statement

See full

Revenue$9.7M-7.1%

Gross profit$8.1M-9.1%

Operating income-$6.2M+49.7%

Net income-$4.8M+53.7%

EPS (diluted)-$0.04+60.0%

Balance sheet

See full

Cash & equivalents$14.6M-37.8%

Total debt$17.5M-7.1%

Total equity$167.9M-15.8%

Total assets$194.5M-15.4%

Cash flow

See full

Operating cash flow-$8.2M+43.3%

CapEx$72.0K-89.0%

Free cash flow-$8.2M+45.3%

Valuation

See full

Market cap$130.15M-46.8%

Enterprise value$133.08M-46.3%

P/S4×-2.8×

Profitability

See full

Gross margin80.5%-0.4pp

Operating margin-141.8%+6.4pp

Net margin-121.2%+12.3pp

FCF margin-90.9%+3.7pp

Returns & leverage

See full

Return on equity-21.3%+2.0pp

Debt / equity0.1×0.0×

Current ratio12×-0.2×

Where this comes from

Reported directly by MaxCyte in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: MaxCyte’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about MaxCyte's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MaxCyte's stock-based comp?: MaxCyte (MXCT) reported stock-based comp of $1.14M in Q1 2026.
How has MaxCyte's stock-based comp changed year-over-year?: MaxCyte's stock-based comp decreased by 62.5% year-over-year, from $3.04M to $1.14M.
What is the long-term trend for MaxCyte's stock-based comp?: Over 4 years (2021 to 2025), MaxCyte's stock-based comp has grown at a 3.7% compound annual growth rate (CAGR), from $7.96M to $9.21M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.